LAVA Therapeutics NV
NASDAQ:LVTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LAVA Therapeutics NV
EPS (Diluted)
LAVA Therapeutics NV
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
EPS (Diluted)
$0
|
CAGR 3-Years
26%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
EPS (Diluted)
€0
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
|
|
Uniqure NV
NASDAQ:QURE
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
argenx SE
XBRU:ARGX
|
EPS (Diluted)
$19
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
EPS (Diluted)
-$5
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-11%
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
See Also
What is LAVA Therapeutics NV's EPS (Diluted)?
EPS (Diluted)
-0.9
USD
Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's EPS (Diluted) amounts to -0.9 USD.
What is LAVA Therapeutics NV's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-20%
Over the last year, the EPS (Diluted) growth was 40%. The average annual EPS (Diluted) growth rates for LAVA Therapeutics NV have been 26% over the past three years , -20% over the past five years .
